Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898829 | 1.00 | HSD17B10 (0.37) | HSD17B10LMNACYP2C19HTTDPP4 | |
| SCHEMBL10205021 | 1.00 | HSD17B10 (0.37) | HSD17B10LMNACYP2C19HTTDPP4 | |
| Hydrochloric Acid SCHEMBL7302950 | 0.98 | HSD17B10 (0.36) | HSD17B10LMNACYP2C19HTTDPP4 | |
| SCHEMBL4901400 | 0.94 | EPHX1 (0.35) | HSD17B10LMNACYP2C19HTTSMN1; SMN2 | |
| SCHEMBL10159973 | 0.88 | HTT (0.42) | HTTDPP4SMN1; SMN2ATMEPHX1 | |
| SCHEMBL22678726 | 0.88 | HTT (0.42) | HTTDPP4SMN1; SMN2ATMEPHX1 | |
| SCHEMBL1074624 | 0.86 | DPP4 (0.38) | HSD17B10LMNACYP2C19DPP4SMN1; SMN2 | |
| SCHEMBL5576808 | 0.82 | DPP4 (0.35) | HSD17B10LMNACYP2C19DPP4SMN1; SMN2 | |
| SCHEMBL17403515 | 0.82 | HSD17B10 (0.38) | HSD17B10LMNACYP2C19HTTDPP4 | |
| SCHEMBL10037292 | 0.82 | HSD17B10 (0.49) | HSD17B10LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-7851467-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7666877-B2 | Ergoline derivatives | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-7534889-B2 | For reduced motility of gastrointestinal tract; irritable bowel syndrome (IBS), chronic constipation, dyspepsia, reflux disease; 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid ((1S,3R,5R)-8-{3-[(2-ethylsulfanylethyl)methanesulfonylamino]-2-hydroxypropyl}-8-aza-bicyclo[3.2.1]oct-3-yl)amide | THERAVANCE, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090018127-A1 | Ergoline Derivatives | NOVARTIS AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20080255187-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-16 | — | — | US | disclosed |
| US-7399862-B2 | 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399862-B2 | 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-17 | — | — | US | disclosed |
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746098-B2 | Proteasome activity enhancing compounds | PSMG3, PSMC1, PSMB11 | HSD17B10 2548/4885LMNA 2899/4885CYP2C19 4746/4885 |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | HSD17B10 2548/4885LMNA 2899/4885CYP2C19 4746/4885 |
| US-20090018127-A1 | Ergoline Derivatives | NR1H2, NR1H3, NR0B1 | HSD17B10 307/4885LMNA 2348/4885CYP2C19 1543/4885 |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | HSD17B10 2638/4885LMNA 4451/4885CYP2C19 228/4885 |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | HSD17B10 2638/4885LMNA 4451/4885CYP2C19 228/4885 |
| US-20080255187-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | HTR4, HTR5A, HTR1A | HSD17B10 2405/4885LMNA 3960/4885CYP2C19 386/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | HSD17B10 3893/4885LMNA 4857/4885CYP2C19 632/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | HSD17B10 4113/4885LMNA 287/4885CYP2C19 2713/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | HSD17B10 3487/4885LMNA 2240/4885CYP2C19 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.